Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inclisiran monotherapy in Chinese adults with elevated LDL-C and low-to-moderate ASCVD risk
CTR20231739Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2023
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of inclisiran in hypercholesterolemia, sponsored by Novartis. Started Jun 2023; status: completed.
02
Drugs
inclisiran
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on CTR20231739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231739.